Liquid Biopsies for Ovarian Carcinoma: Potential Clinical Values of Circulating Acellular miRNA in Patients with Ovarian Cancer
Department of Obstetrics and Gynecology, Taizhou People’s Hospital, No. 399 Hailing South Road, Taizhou, Jiangsu 225300, China, 1Graduate School of Dalian Medical University, No. 9 Lushun South Road, Dalian, Liaoning 116027, China, 2Department of Surgery, Taizhou Maternity Hospital, No. 568 Dongfeng South Road, Taizhou, Jiangsu 225300, China
Department of Surgery, Taizhou Maternity Hospital, No. 568 Dongfeng South Road, Taizhou, Jiangsu 225300, China, E-mail: email@example.com
The aim of this study was to investigate liquid biopsies of ovarian cancer to provide a more adequate basis for its treatment. Forty four patients with ovarian cancer and 47 healthy people were enrolled in this study from the Second Affiliated Hospital of Soochow Universit Changed to “ Taizhou People’s Hospital between February 2017 and December 2018 for analysis. The expression of miRNA-21-5p and B-cell translocation gene 2 mRNA was determined using reverse transcription polymerase chain reaction, the target genes of miRNA-21-5p were predicted by databases and the expression of B-cell translocation gene 2 protein was detected by western blot. ES-2 cells were used as model group and normal ovarian epithelial cells served as the control group. The results showed that miRNA-21-5p was highly expressed in the serum of patients with ovarian cancer. Through the databases prediction and the intersection of multiple databases, B-cell translocation gene 2 was found to be a downstream target gene regulated by miRNA-21-5p and its expression was negatively correlated with B-cell translocation gene 2 by transfection of miRNA-21-5p inhibitor. MiRNA-21-5p is highly expressed in ovarian cancer cells, and it can be used to treat ovarian cancer by up-regulating the expression of the target gene B-cell translocation gene 2. MiRNA-21-5p can be used as a biological marker, which may inhibit the proliferation of cancer cells by up-regulating B-cell translocation gene 2 gene to treat ovarian cancer.